<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02929862</url>
  </required_header>
  <id_info>
    <org_study_id>LYC-55716-1001</org_study_id>
    <nct_id>NCT02929862</nct_id>
  </id_info>
  <brief_title>Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer</brief_title>
  <official_title>A Phase 1/2A Multicenter, Open-Label Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lycera Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lycera Corp.</source>
  <brief_summary>
    <textblock>
      This is a Phase 1/2A study designed to evaluate the safety and tolerability of increased&#xD;
      repeated doses of LYC-55716 in subjects with locally advanced or metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 30 subjects across approximately 5 United States (US) sites will be enrolled in&#xD;
      the Phase 1 portion of the study and approximately 69-84 subjects across approximately 15 US&#xD;
      sites will be enrolled in the Phase 2A portion of the study.&#xD;
&#xD;
      The Phase 1 portion of the study will follow a 3 + 3 dose-escalation design to evaluate&#xD;
      twice-daily (BID) administration of LYC-55716 for DLTs and to determine the MTD and the RP2D&#xD;
      for further assessment in Phase 2A. A treatment cycle will consist of 28 days of treatment&#xD;
      and subjects may continue to receive subsequent cycles of therapy as long as they do not have&#xD;
      clinically significant progressive disease.&#xD;
&#xD;
      In the Phase 2A portion of the study, 69-84 subjects with locally advanced or metastatic&#xD;
      solid tumors considered most likely to be responsive to a RORγ agonist will be enrolled and&#xD;
      treated at the MTD or RP2D.&#xD;
&#xD;
      Six cohorts of subjects with advanced cancer will be enrolled. Cohorts 1 to 3 will enroll 14&#xD;
      to 19 subjects per cohort. Tumor types include NSCLC (Cohort 1); gastric, esophageal and G-E&#xD;
      junction adenocarcinoma (Cohort 2); and SCCHN (Cohort 3). Cohorts 4 to 6 will enroll up to 9&#xD;
      subjects per cohort. Tumor types include ovarian carcinoma (Cohort 4), renal cell carcinoma&#xD;
      (Cohort 5), and urothelial carcinoma (Cohort 6).&#xD;
&#xD;
      Primary Study Objectives&#xD;
&#xD;
      Phase 1&#xD;
&#xD;
        -  Evaluate the safety and tolerability of LYC-55716&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D)&#xD;
&#xD;
      Phase 2A&#xD;
&#xD;
      • Determine the objective response rate according to response evaluation criteria in solid&#xD;
      tumors (RECIST) v1.1.&#xD;
&#xD;
      Secondary Study Objectives&#xD;
&#xD;
      Phase 1&#xD;
&#xD;
        -  Evaluate the activity of LYC-55716 by objective response according to RECIST v1.1.&#xD;
&#xD;
        -  Determine the durability of any observed objective response&#xD;
&#xD;
      Phase 2A&#xD;
&#xD;
        -  Determine the duration of response&#xD;
&#xD;
        -  Determine progression-free survival (PFS) and overall survival (OS)&#xD;
&#xD;
        -  Determine suitability of the RP2D for further study&#xD;
&#xD;
        -  Characterize the pharmacokinetics (PK) of LYC-55716&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Actual">May 31, 2019</completion_date>
  <primary_completion_date type="Actual">May 31, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess Tumor Activity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Evaluated according to RECIST v1.1</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Single Agent 55716</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LYC-55716</intervention_name>
    <description>For Phase 1, increasing doses of oral 55716 given BID for a 28 day cycle. For Phase 2A, the RP2D will be administered to patients for 28 day cycles.</description>
    <arm_group_label>Single Agent 55716</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is male or female and at least 18 years of age.&#xD;
&#xD;
          -  Histological or cytological confirmation of advanced unresectable solid tumors,&#xD;
             including those subjects who have progressed on standard anticancer therapy and for&#xD;
             whom no further therapy that confers clinical benefit is available.&#xD;
&#xD;
          -  Subject has an Eastern Cooperative Oncology Group (ECOG) score of 0 1 or Karnofsky&#xD;
             Performance Status Score ≥ 70.&#xD;
&#xD;
          -  Subject has a life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  Subject has adequate organ function as determined by the following laboratory values:&#xD;
&#xD;
               -  Absolute Neutrophil Count* ≥ 1,500/mm3 (≥ 1.5 x 109/L)&#xD;
&#xD;
               -  Platelets* ≥ 100,000/mm3 (≥ 100 x 109/L)&#xD;
&#xD;
               -  Lymphocytes ≥ 0.5 x 109/L&#xD;
&#xD;
               -  Hemoglobin* &gt; 9.0 g/dL&#xD;
&#xD;
               -  Serum Creatinine or Creatinine Clearance** ≤ 1.5 x ULN, &gt; 50 mL/min&#xD;
&#xD;
               -  Total Serum Bilirubin ≤ 1.5 x ULN (&lt; 3.0 mg/dL if subject has Gilbert's syndrome)&#xD;
&#xD;
               -  Liver Transaminases (ALT/AST) ≤ 2.5 x ULN, ≤ 5.0 x ULN if liver metastases&#xD;
                  present&#xD;
&#xD;
                    -  (* = without ongoing growth factor or transfusion support)&#xD;
&#xD;
                    -  (** = calculated by Cockcroft and Gault's formula)&#xD;
&#xD;
                    -  (ALT = alanine aminotransferase, AST = aspartate aminotransferase, ULN =&#xD;
                       upper limit of normal)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has received an investigational drug in the 28 day period before the first&#xD;
             dose of study drug (or within 5 half-lives if longer) or is currently participating in&#xD;
             another interventional clinical trial.&#xD;
&#xD;
          -  Subject has known symptomatic brain metastases or leptomeningeal involvement as&#xD;
             assessed by CT scan or MRI. Subjects with stable asymptomatic brain metastases or&#xD;
             leptomeningeal disease are eligible if they have not required new treatments for this&#xD;
             disease in a 28 day period before the first dose of study drug, and anticonvulsants&#xD;
             and steroids have not been administered for a period of 2 weeks prior to the first&#xD;
             dose of study drug.&#xD;
&#xD;
          -  Subject has not recovered from adverse reactions to prior cancer treatment or&#xD;
             procedures (surgery, chemotherapy, immunotherapy, radiation therapy) to Common&#xD;
             Terminology Criteria for Adverse Events (CTCAE) Grade 2 or better.&#xD;
&#xD;
          -  Subject has a previous (within 5 years) or current malignancy other than the target&#xD;
             cancer with the exception of curatively treated local tumors such as carcinoma in situ&#xD;
             of the breast or cervix, basal or squamous cell carcinoma of the skin, or prostate&#xD;
             cancer with Gleason Grade &lt; 6 and prostate-specific antigen within normal range.&#xD;
&#xD;
        Modifications to Eligibility Criteria for the following specific tumor types:&#xD;
&#xD;
        Phase 2A will be limited to enrolling the following tumor types:&#xD;
&#xD;
          -  NSCLC&#xD;
&#xD;
          -  Gastric, Esophageal, and G-E Junction Adenocarcinoma&#xD;
&#xD;
          -  SCCHN&#xD;
&#xD;
          -  Ovarian Carcinoma&#xD;
&#xD;
          -  Renal Cell Carcinoma&#xD;
&#xD;
          -  Urothelial Carcinoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycera Investigational Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>October 5, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2016</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

